Biomarin Pharmaceutical Inc. - Registered Shares

Biomarin Pharmaceutical Inc. - Registered Shares

BMRN

Get informed when a big investor buys or sells

+ Follow
Market Cap$12.89B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Biomarin Pharmaceutical Inc. - Registered SharesBiomarin Pharmaceutical Inc. - Registered Shares175.5-1%3.90.7
$91.23

Target Price by Analysts

36.2% upsideBiomarin Pharmaceutical - Registered Shares Target Price DetailsTarget Price
$133.10

Current Fair Value

98.7% upside

Undervalued by 98.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$12.89 Billion
Enterprise Value$16.22 Billion
Dividend Yield$- (-)
Earnings per Share$1.82
Beta0.23
Outstanding Shares192,959,000

Return

Return on Equity1.15%ROE
Return on Assets0.62%
Return on Invested Capital0.76%

Valuation & Multiples

P/E Ratio175.53P/E Ratio
PEG-215.66PEG
Price to Sales3.94Price to Sales
Price to Book Ratio2.09Price to Book Ratio
Enterprise Value to Revenue4.76
Enterprise Value to EBIT212.82
Enterprise Value to Net Income222
Total Debt to Enterprise0.26
Debt to Equity0.66Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 6, 2026
EPS Estimate
$0.95
Average shareholder expectation
Revenue Estimate
$932.03 M
Average shareholder expectation

Next Earnings Call

Expected Date
October 26, 2026
EPS Estimate
$1.37
Average shareholder expectation
Revenue Estimate
$1.03 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.3730▼ 36.44%
Total Calls1,746,596▲ 17.21%
Total Puts651,500▼ 40.71%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %100.80%▲ 5.39%
Total Invested$11.10B▲ 7.04%
Investors Holding576▼ 6.00%

ESG Score

No data

About Biomarin Pharmaceutical Inc.

CEO: Jean-Jacques Bienaime